Related Experiment Video
Updated: Aug 25, 2026
Dual-modality Molecular Cartography: Integrating Multiplex mRNA Detection with Protein Imaging Mass Cytometry
Published on: November 14, 2025
Identifying multiple tumor-specific epitopes from large-scale screening for overexpressed mRNA
Søren Buus1, Mogens Helweg Claesson
1Institute of Medical Microbiology and Immunology, and Department of Medical Anatomy, The Panum Institute, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark. sb@immi.ku.dk
Abstract:
The rationale of a T-cell epitope-based approach to cancer treatment is primarily rooted in the hypothesis that CD8(+) cytotoxic T cells (CTLs) can be manipulated to specifically identify and kill cancer cells. A solid understanding of CTL specificity and activation is a fundamental requirement for tumor immunotherapy. The means to identify tumor-specific CTL epitopes and to monitor corresponding CTL responses are important enabling technologies. Recent advances in these enabling technologies include their ability to exploit genomic, transcriptomic and proteomic information. These advances constitute new opportunities, which will enable approaches to tumor immunotherapy that encompass both human diversity and tumor heterogeneity, increase the efficacy of tumor immunotherapy and potentially provide the opportunity for individualized therapy.
Insights
Harnessing CD8(+) cytotoxic T cells (CTLs) for cancer treatment relies on understanding T-cell epitopes. Advances in genomic and proteomic technologies enhance tumor immunotherapy strategies.
Area of Science:
- Immunology
- Oncology
- Bioinformatics
Background:
- Cancer immunotherapy aims to leverage the immune system to eliminate malignant cells.
- CD8(+) cytotoxic T lymphocytes (CTLs) are key mediators of anti-tumor immunity, recognizing specific tumor antigens.
- Effective cancer treatment requires a deep understanding of CTL specificity and activation pathways.
Purpose of the Study:
- To explore the rationale behind T-cell epitope-based cancer treatment strategies.
- To highlight the importance of identifying tumor-specific CTL epitopes and monitoring CTL responses.
- To discuss how recent technological advancements can improve tumor immunotherapy.
Main Methods:
- Leveraging genomic, transcriptomic, and proteomic data to identify T-cell epitopes.
- Developing technologies to monitor T-cell responses against tumor antigens.
- Analyzing CTL specificity and activation mechanisms.
Main Results:
- Recent technological advances provide new opportunities for T-cell epitope discovery.
- These advances enable the development of more effective tumor immunotherapy approaches.
- The potential for individualized cancer therapy based on T-cell epitopes is increased.
Conclusions:
- T-cell epitope-based strategies hold significant promise for cancer treatment.
- Exploiting genomic and proteomic data is crucial for advancing tumor immunotherapy.
- Future approaches can enhance efficacy and enable personalized cancer therapies.
